Meda AB’s (OMX: MEDA A) first quarter net sales reach 3.375 billion Swedish kronor, which is up strongly from just under 3 billion one year ago. Profit numbers show more modest development as margins were under pressure: EBITDA 1.15 billion, operating profit of 618 million and profit after tax of 370 million are rather close to comparison period. Earnings per share are exactly the same at 1.12 SEK. The full report is available here.
The company highlights the very recent FDA approval of intranasal seasonal allergic rhinitis therapy Dymista. The condition affects about 60 million people in the United States annually and as many as 500 million world-over. The company conducted studies in over 4000 patients and has long-term data from more than 600. It has previously quoted some meta-analysis and believes it could be the drug of choice with clear blockbuster potential. Meda is hoping for a European approval in 2013.
No comments:
Post a Comment